Core Viewpoint - Koyuan Pharmaceutical has decided to terminate the issuance of shares for asset acquisition and related fundraising due to changes in the market environment, aiming to protect the long-term interests of all shareholders [1] Group 1: Termination of Acquisition - The board of Koyuan Pharmaceutical has approved the termination of the share issuance for acquiring 99.42% of Hongjitang for a consideration of 3.58 billion yuan and raising up to 700 million yuan in supporting funds [1] - The termination is described as a prudent decision to maintain the long-term interests of shareholders, with no significant adverse impact on the company's current operations [1] Group 2: Business Performance - For the first three quarters of the year, Koyuan Pharmaceutical reported revenue of 303 million yuan, a year-on-year decrease of 8.5%, and a net profit attributable to shareholders of 31.47 million yuan, down 20.7% [2] - The company's operating cash flow net amount was 27.24 million yuan, showing a year-on-year increase of 14.1% [2] Group 3: Strategic Developments - Koyuan Pharmaceutical's subsidiary, Linuo Pharmaceutical, has had its intelligent manufacturing project for injectables included in the list of major industrial projects for the province's new and old kinetic energy conversion in 2025 [2] - The intelligent manufacturing project, completed on September 28, covers an area of approximately 46,000 square meters and includes key areas such as quality inspection and R&D buildings, high-end injectable production workshops, and a comprehensive intelligent warehouse [2] - The project aims to leverage industrial internet, artificial intelligence, and big data technologies to create a comprehensive smart control system from R&D to production, meeting the standards of China GMP, US FDA, and EU GMP [2][3] Group 4: Future Outlook - Koyuan Pharmaceutical plans to use the inclusion of its project as an opportunity to increase innovation investment and empower industrial upgrades, contributing to the high-quality development of the pharmaceutical industry in Shandong Province [3]
科源制药终止并购宏济堂 因市场环境变化